Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab.
Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab.
复制标题
DOI：
10.2169/internalmedicine.9701-22
复制
发表时间：
2023-02-15
影响因子：
1.2
通讯作者：
Nakagawa, Hayato
中科院分区：
文献类型：
--
作者：
Shigefuku, Ryuta;Yoshikawa, Kyoko;Tsukimoto, Mone;Owa, Hirono;Tamai, Yasuyuki;Tameda, Masahiko;Ogura, Suguru;Sugimoto, Ryosuke;Tanaka, Hideaki;Eguchi, Akiko;Sugimoto, Kazushi;Hasegawa, Hiroshi;Iwasa, Motoh;Nakagawa, Hayato
1例70岁男性被诊断为肝细胞癌（HCC）伴门静脉浸润和肺转移，开始atezolizumab+贝伐珠单抗（ATZ/BEV）治疗。两个月后，计算机断层扫描显示肿瘤生长伴随腹水，右心室侵犯，肺转移恶化，和主要门静脉侵犯。然而，ATZ/BEV的继续导致所有病变的尺寸显著减小，最终导致在治疗9个周期后血管浸润和肺转移消失。认为肿瘤生长反映了假进展，其难以与超进展区分。我们在此报告了一个显著的肝癌假进展ATZ/BEV的情况。
A 70-year-old man was diagnosed with hepatocellular carcinoma (HCC) with portal vein invasion and lung metastases, for which atezolizumab plus bevacizumab (ATZ/BEV) was initiated. After two months, computed tomography revealed tumor growth accompanied by ascites, right ventricular invasion, exacerbation of the lung metastases, and main portal vein invasion. However, continuation of ATZ/BEV caused remarkable size reductions in all lesions, finally resulting in the disappearance of the vascular invasion and lung metastases after nine cycles of treatment. The tumor growth was considered to reflect pseudoprogression, which is difficult to distinguish from hyperprogression. We herein report a remarkable HCC case of pseudoprogression on ATZ/BEV.
登录
查看更多内容
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
影响因子：
64.8
作者：
Pfister D;Núñez NG;Pinyol R;Govaere O;Pinter M;Szydlowska M;Gupta R;Qiu M;Deczkowska A;Weiner A;Müller F;Sinha A;Friebel E;Engleitner T;Lenggenhager D;Moncsek A;Heide D;Stirm K;Kosla J;Kotsiliti E;Leone V;Dudek M;Yousuf S;Inverso D;Singh I;Teijeiro A;Castet F;Montironi C;Haber PK;Tiniakos D;Bedossa P;Cockell S;Younes R;Vacca M;Marra F;Schattenberg JM;Allison M;Bugianesi E;Ratziu V;Pressiani T;D'Alessio A;Personeni N;Rimassa L;Daly AK;Scheiner B;Pomej K;Kirstein MM;Vogel A;Peck-Radosavljevic M;Hucke F;Finkelmeier F;Waidmann O;Trojan J;Schulze K;Wege H;Koch S;Weinmann A;Bueter M;Rössler F;Siebenhüner A;De Dosso S;Mallm JP;Umansky V;Jugold M;Luedde T;Schietinger A;Schirmacher P;Emu B;Augustin HG;Billeter A;Müller-Stich B;Kikuchi H;Duda DG;Kütting F;Waldschmidt DT;Ebert MP;Rahbari N;Mei HE;Schulz AR;Ringelhan M;Malek N;Spahn S;Bitzer M;Ruiz de Galarreta M;Lujambio A;Dufour JF;Marron TU;Kaseb A;Kudo M;Huang YH;Djouder N;Wolter K;Zender L;Marche PN;Decaens T;Pinato DJ;Rad R;Mertens JC;Weber A;Unger K;Meissner F;Roth S;Jilkova ZM;Claassen M;Anstee QM;Amit I;Knolle P;Becher B;Llovet JM;Heikenwalder M
通讯作者：
Heikenwalder M
DOI：
10.1177/23247096211058489
发表时间：
2021-01
影响因子：
1.2
作者：
Watanabe Y;Ogawa M;Tamura Y;Suda S;Kaneko M;Kumagawa M;Hirayama M;Matsumoto N;Yamamoto T;Moriyama M
通讯作者：
Moriyama M
影响因子：
5.1
作者：
Grierson P;Crites D;Ruzinova MB;Yano M;Lim KH
通讯作者：
Lim KH
纳武单抗用于治疗复发性头颈鳞状细胞癌。
DOI：
10.1056/nejmoa1602252
发表时间：
2016-11-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Ferris RL;Blumenschein G Jr;Fayette J;Guigay J;Colevas AD;Licitra L;Harrington K;Kasper S;Vokes EE;Even C;Worden F;Saba NF;Iglesias Docampo LC;Haddad R;Rordorf T;Kiyota N;Tahara M;Monga M;Lynch M;Geese WJ;Kopit J;Shaw JW;Gillison ML
通讯作者：
Gillison ML